- The report contains detailed information about Genta Incorporated that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Genta Incorporated. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Genta Incorporated financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Genta Incorporated competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Genta Incorporated business.
About Genta Incorporated
Genta Incorporated, a biopharmaceutical company, engages in the identification, research, development, and commercialization of pharmaceutical drugs for the treatment of cancer and related diseases.
Research and Development Programs
The companys research portfolio consists of two major programs: DNA/RNA Medicines; and Small Molecules.
The DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that can be used to treat disease. These technologies include antisense, decoys, and small interfering or micro RNAs.
Genasense: The companys primary drug from this program is an investigational antisense compound known as Genasense (oblimersen sodium injection). Genasense is designed to disrupt a specific messenger RNA (mRNA), which then block the production of a protein known as Bcl-2, a protein that is central to the process of apoptosis. It primarily focuses on the development, regulatory approval, and commercialization of Genasense in three diseases: melanoma; chronic lymphocytic leukemia (CLL); and non-Hodgkins lymphoma (NHL). In 2009, the company completed accrual to a Phase 3 trial of Genasense plus chemotherapy in advanced melanoma.
Ganite: The company is marketing Ganite in the U.S., which is an intravenous formulation of gallium, for treatment of cancer-related hypercalcemia that is resistant to hydration.
Tesetaxel: The company is also developing tesetaxel as an oral agent that targets tubulin in cancer cells. It has obtained a worldwide license for tesetaxel from Daiichi Sankyo Company Ltd. Tesetaxel is a taxane compound that is taken by mouth. In January 2009, the company initiated of a new clinical trial with tesetaxel to examine the clinical pharmacology of the drug over a narrow dosing range around the established Phase 2 dose. The company has received designations of tesetaxel as an orphan drug for treatment of patients with advanced gastric cancer and for patients with advanced melanoma. Its priorities for clinical testing of tesetaxel include the evaluation of safety and efficacy in patients with advanced gastric cancer, advanced melanoma and prostate cancer. Other disease priorities for clinical research include cancers of the bladder and breast.
Oral Gallium-Containing Compounds: The companys third pipeline project consists of various formulations of an oral gallium-containing compound. One of these formulations is known as G4544, which is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite.
Genta Incorporated was founded in 1988.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. GENTA INCORPORATED COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. GENTA INCORPORATED BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. GENTA INCORPORATED SWOT ANALYSIS
4. GENTA INCORPORATED FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. GENTA INCORPORATED COMPETITORS AND INDUSTRY ANALYSIS
5.1. Genta Incorporated Direct Competitors
5.2. Comparison of Genta Incorporated and Direct Competitors Financial Ratios
5.3. Comparison of Genta Incorporated and Direct Competitors Stock Charts
5.4. Genta Incorporated Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Genta Incorporated Industry Position Analysis
6. GENTA INCORPORATED NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. GENTA INCORPORATED EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. GENTA INCORPORATED ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. GENTA INCORPORATED IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. GENTA INCORPORATED PORTER FIVE FORCES ANALYSIS2
12. GENTA INCORPORATED VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Genta Incorporated Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Genta Incorporated Key Executives
Key Executives Biographies1
Key Executives Compensations1
Genta Incorporated Major Shareholders
Genta Incorporated History
Genta Incorporated Products
Revenues by Segment
Revenues by Region
Genta Incorporated Offices and Representations
Genta Incorporated SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Genta Incorporated Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Genta Incorporated Capital Market Snapshot
Genta Incorporated Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Genta Incorporated Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Genta Incorporated Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Genta Incorporated Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Genta Incorporated 1-year Stock Charts
Genta Incorporated 5-year Stock Charts
Genta Incorporated vs. Main Indexes 1-year Stock Chart
Genta Incorporated vs. Direct Competitors 1-year Stock Charts
Genta Incorporated Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?